Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. - Wikidata - awgldk - TriplyDB

Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.

Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.

http://www.wikidata.org/entity/Q34652972

about

Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol.Identification of potential target genes associated with the effect of propranolol on angiosarcoma via microarray analysis Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth.Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma.A genomics approach to identify susceptibilities of breast cancer cells to "fever-range" hyperthermia.Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.A hydrogel-endothelial cell implant mimics infantile hemangioma: modulation by survivin and the Hippo pathway.Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation.Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system.Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.Metastatic Primary Angiosarcoma of the Breast: Can We Tame It the Metronomic Way.Beta-adrenergic receptors are expressed across diverse cancers.Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma.Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update.Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and β2AR-Dependent Neo-Angiogenic Switch.The role of β-blockers in dermatological treatment: a review.Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma.Endothelial cell malignancies: new insights from the laboratory and clinic.Vascular tumours of the liver: a particular story Propranolol for the treatment of vascular sarcomas Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment

P2860

Q33431654-80AD6480-D79F-48DD-AD77-AF9F8A981175 Q33750708-B9999DEF-886A-4088-8A44-CABCE62C8653 Q33909559-B1013CFF-A3DC-4059-835E-E8FE48FDDBFF Q35002582-28C4180F-C6C2-45C6-8319-1587F2D1F0B3 Q35089808-738166FC-C008-4F14-864F-EEB0A1BA5BE7 Q36389964-7D765FD7-13D1-4C97-9B49-E50156D3A844 Q36790748-BB21F12F-1EEF-4AA7-AC42-118F8240CA60 Q37404693-639A572B-C025-4292-85EE-F2F20C9B5403 Q37688636-77C15BAE-3FB4-493C-BDAE-783DAB58D515 Q37701617-9856B00E-0497-446B-BDF5-ECDD74D64B36 Q38293740-1055B525-95D7-4622-A18D-449FCE9D2B19 Q38769283-733803DB-008E-4CA3-9976-8267243B6697 Q39910979-FDF5E290-75BB-4607-BBC8-41D6A0980180 Q41601904-AB9198EC-717E-4963-9C13-7C3BDDEAE389 Q41667468-71D696EF-6005-49DF-80D5-A9DB946C3A28 Q41783972-D1BA3154-9AC1-47A3-AA3A-72550E2BFC62 Q41970819-767B4369-EDCF-4FD1-BFF6-062531F7AA23 Q47101799-B2319709-141E-43DA-BB7B-0AB571249407 Q47122078-50834D0C-2F1E-464A-99B1-DAFB51AB0C4B Q47944205-2F70FBFC-AC12-4C43-BFCF-02D354519B75 Q50282860-A47BCDCC-D159-4EC2-8057-1E7597A853D2 Q55192373-758D036F-C7EB-4FAE-B71E-8A306FC687A5 Q55332047-5499E567-3FAB-4E6D-AF8E-915ED7A4CD1E Q58554779-4F626571-07F7-4B79-87F2-E30DB2A71B56 Q58761654-316D9C78-494D-45E7-9F71-82BCA4A1B286 Q58788212-A049414B-F41A-4C20-ADBE-7FE27949366E Q59136527-165C5FB8-746B-4E68-89E8-4D81174F5463

P2860

Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.

http://www.wikidata.org/entity/Q34652972

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@ast

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@en

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@nl

type

label

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@ast

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@en

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@nl

prefLabel

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@ast

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@en

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@nl

P1433

Q34652972-A6449965-B116-4875-8A57-BEF9F87283E1

P1476

Q34652972-50C22EBB-E595-4E8C-A3C1-7333B0070FD2

P2093

Q34652972-18E29E51-1515-44DE-BFB8-5F20B75A4B15

Q34652972-20C4F076-0EAB-4C3D-A61F-BEB4F8DB558B

Q34652972-2955C1FF-0156-4216-BC27-16053BAD8C53

Q34652972-3BE28B13-3A39-49AC-9292-7C222562A7E0

Q34652972-48F489AF-0A71-496A-8C20-2E1E73174032

Q34652972-6C5ACB3F-E9F6-4963-A335-4A5D52A87F08

Q34652972-A3DE198A-CCAC-465C-BBE0-A5DB6A58C3DB

Q34652972-A5E0E118-D218-4AE0-A5D9-03E229843970

Q34652972-B93AF26A-AB28-44A4-A68A-9C25AF46176D

Q34652972-F9491386-A7C0-49E3-B64D-06FB8E3D8BDA

P2860

Q34652972-090A226A-B90F-4364-B91E-05885A803C06

Q34652972-12CF61A6-264D-40B8-992D-E4C946B51453

Q34652972-139A2EE8-B214-4E20-A130-C5BA38416A3B

Q34652972-1511DA04-E5CB-4120-9945-EBAC6653DF84

Q34652972-15826F52-DE3B-4E2F-9AF3-3DA6847F1EFD

Q34652972-1C6886AB-C845-4A6C-82C9-C404ACB8B39A

Q34652972-444FCC64-EE80-4971-9BC9-D27B6E997D03

Q34652972-4683E54C-D62B-49F4-900C-ACFCF583CF34

Q34652972-527A7C0F-674C-40AF-AFAD-D3117AE6491E

Q34652972-56C6AD32-7A48-4C06-83EC-EEA8998BA5B3

P304

Q34652972-1E814F39-FFA8-417F-BACF-E02FFEAD8B1D

P31

Q34652972-262CCD68-E9AE-4EC0-8450-F98062981977

P356

Q34652972-B715D6B4-772C-4925-BDE3-2E7BA5649B40

P407

Q34652972-841F8AAA-307F-4037-A95E-1547688D1584

P433

Q34652972-DC815C5D-68CC-4150-AFB1-4553FF2FB166

P478

Q34652972-C1FEE664-CB31-46E1-B6AB-0CCD85F598ED

P50

Q34652972-0CCAF960-6C28-4E51-9601-3CC5DDD52994

P577

Q34652972-8F88EDB6-60C3-4CD0-86A2-78918D07FF35

P5875

Q34652972-235B2822-B3AB-40FC-AD33-20516B77F4FD

P698

Q34652972-95E294F5-350B-4F50-BB1C-6547D8D60653

P932

Q34652972-1EA394F8-017D-4CEE-8528-2A33393C4154

P356

JOURNAL.PONE.0060021

P1433

P1476

Targeting of beta adrenergic r ...... endothelioma and angiosarcoma.

@en

P2093

Brad A Bryan

http://www.w3.org/2001/XMLSchema#string

Clarissa Amaya

http://www.w3.org/2001/XMLSchema#string

Dianne C Mitchell

http://www.w3.org/2001/XMLSchema#string

Dolores Diaz

http://www.w3.org/2001/XMLSchema#string

James Battiste

http://www.w3.org/2001/XMLSchema#string

Jessica M Stiles

http://www.w3.org/2001/XMLSchema#string

Laura E Boucheron

http://www.w3.org/2001/XMLSchema#string

Robert Pham

http://www.w3.org/2001/XMLSchema#string

Steven Rains

http://www.w3.org/2001/XMLSchema#string

Victor Kokta

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed

Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.

The sympathetic nervous system induces a metastatic switch in primary breast cancer.

Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

Molecular control of angiopoietin signalling.

Management of angiosarcoma.

Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells.

Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival

P304

e60021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0060021

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236106723

http://www.w3.org/2001/XMLSchema#string

P698

23555867

http://www.w3.org/2001/XMLSchema#string

P932

3610939

http://www.w3.org/2001/XMLSchema#string